SLNO and NBIX Related Headlines
Go Back- Neurocrine Bio. (NBIX) PT Raised to $185 at Morgan Stanley
- Neurocrine Bio. (NBIX) PT Raised to $200 at Canaccord
- Neurocrine Bio. (NBIX) PT Raised to $220 at Oppenheimer on SLNO deal
- Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout
- Neurocrine to acquire Soleno Therapeutics for $2.9 billion in cash deal
- Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
- Neurocrine Biosciences nearing over $2.5B deal for Soleno Therapeutics
